Key facts
- Alessa Therapeutics’s last known valuation is $49.0M (Apr 2025).
- It has raised $31.6M across 3 recorded rounds; the latest was Early Stage VC ($25.4M) in Apr 2025.
- Notable investors include National Institutes of Health, Mission BioCapital, University of California San Francisco Foundation, Cure Ventures, Johnson & Johnson — 10 tracked in total.
- Alessa Therapeutics has filed 3 Form Ds with the SEC since 2019, most recently May 2025 ($25.4M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Alessa Therapeutics
Funding rounds
3 roundsAbout Alessa Therapeutics
Developer of a drug delivery implantable system designed to treat patients with prostate cancer. The company's system helps to administer anti-androgen drugs to the tumor in the prostate through a sustained and localized system without systemic exposure, enabling patients to have localized treatments for solid organ disease.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2018
- Employees
- 13
- Website
- alessatherapeutics.com/
- Ownership
- Privately Held (backing)
Alessa Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alessa Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alessa Therapeutics in its N-PORT filings yet. We sweep new filings monthly.